HK1250582A1 - 癌症标志物pd-ecgf - Google Patents

癌症标志物pd-ecgf Download PDF

Info

Publication number
HK1250582A1
HK1250582A1 HK18109182.9A HK18109182A HK1250582A1 HK 1250582 A1 HK1250582 A1 HK 1250582A1 HK 18109182 A HK18109182 A HK 18109182A HK 1250582 A1 HK1250582 A1 HK 1250582A1
Authority
HK
Hong Kong
Prior art keywords
cancer
ecgf
biomarker
response
predicting
Prior art date
Application number
HK18109182.9A
Other languages
English (en)
Chinese (zh)
Inventor
O‧卡萨诺瓦卡萨诺瓦
O‧卡薩諾瓦卡薩諾瓦
G‧吉梅内斯瓦莱里奥
M‧奥乔亚德奥尔扎
G‧吉梅內斯瓦萊里奧
V‧纳瓦罗佩雷斯
N‧巴萨尼
M‧奧喬亞德奧爾扎
H‧维达格尔
V‧納瓦羅佩雷斯
N‧巴薩尼
H‧維達格爾
Original Assignee
生物医学研究所(Idibell)
生物醫學研究所(Idibell)
加泰维尼亚肿瘤研究所(Ico)
加泰維尼亞腫瘤研究所(Ico)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物医学研究所(Idibell), 生物醫學研究所(Idibell), 加泰维尼亚肿瘤研究所(Ico), 加泰維尼亞腫瘤研究所(Ico) filed Critical 生物医学研究所(Idibell)
Publication of HK1250582A1 publication Critical patent/HK1250582A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18109182.9A 2015-03-11 2016-03-10 癌症标志物pd-ecgf HK1250582A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382109.5 2015-03-11
EP15382109.5A EP3067698A1 (en) 2015-03-11 2015-03-11 Pd-ecgf as biomarker of cancer
PCT/EP2016/055143 WO2016142471A1 (en) 2015-03-11 2016-03-10 Pd-ecgf as biomarker of cancer

Publications (1)

Publication Number Publication Date
HK1250582A1 true HK1250582A1 (zh) 2019-01-04

Family

ID=52737037

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109182.9A HK1250582A1 (zh) 2015-03-11 2016-03-10 癌症标志物pd-ecgf

Country Status (11)

Country Link
US (2) US11802874B2 (cg-RX-API-DMAC7.html)
EP (2) EP3067698A1 (cg-RX-API-DMAC7.html)
JP (3) JP2018512585A (cg-RX-API-DMAC7.html)
KR (1) KR102513020B1 (cg-RX-API-DMAC7.html)
CN (1) CN107667292B (cg-RX-API-DMAC7.html)
AU (1) AU2016231086B8 (cg-RX-API-DMAC7.html)
ES (1) ES2896056T3 (cg-RX-API-DMAC7.html)
HK (1) HK1250582A1 (cg-RX-API-DMAC7.html)
MX (1) MX384046B (cg-RX-API-DMAC7.html)
PL (1) PL3268744T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016142471A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740755B9 (en) * 2018-01-15 2023-10-04 Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) Use of the tas1r3 protein as a marker for therapeutic, diagnostic, and/or prognostic purposes for tumors that express said protein
US12624695B2 (en) 2024-09-19 2026-05-12 Mahle International Gmbh Oil separator for compressor and compressor with oil separator

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3268147B2 (ja) * 1994-12-28 2002-03-25 大鵬薬品工業株式会社 モノクローナル抗体
WO2003086299A2 (en) 2002-04-09 2003-10-23 Government Of The United States Of America, Represnted By The Secretary, Department Of Health And Huuman Service Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
EP1510588B1 (en) 2003-08-28 2007-01-31 Roche Diagnostics GmbH Correlation of the ratio of thymidine phosphorylase and dihydropyrimidine dehydrogenase mRNA expression levels in colorectal cancer with disease-free survival in 5-FU treated patients
WO2007115376A1 (en) 2006-04-11 2007-10-18 The University Of Western Australia Anti-angiogenic agents and methods of their use
US8642349B1 (en) * 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
US20120282631A1 (en) * 2009-03-20 2012-11-08 The Hong Kong Polytechnic University Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers
US8110675B2 (en) 2009-06-15 2012-02-07 Chang Gung University TP expression-inhibiting compound and siRNA sequence thereof
US20100317029A1 (en) * 2009-06-15 2010-12-16 Lih-Chyang Chen Nasopharyngeal cancer malingancy biomarker and method thereof
CN101993919A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用
AU2011223789A1 (en) * 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
JP2014523398A (ja) 2011-03-23 2014-09-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Also Published As

Publication number Publication date
US12298307B2 (en) 2025-05-13
EP3268744B1 (en) 2021-08-11
JP2018512585A (ja) 2018-05-17
AU2016231086B8 (en) 2022-02-03
AU2016231086A1 (en) 2017-09-28
US11802874B2 (en) 2023-10-31
CA2978653A1 (en) 2016-09-15
CN107667292B (zh) 2020-06-19
WO2016142471A1 (en) 2016-09-15
AU2016231086B2 (en) 2021-08-12
US20240069029A1 (en) 2024-02-29
MX2017011467A (es) 2018-01-23
KR20170123638A (ko) 2017-11-08
ES2896056T3 (es) 2022-02-23
EP3067698A1 (en) 2016-09-14
KR102513020B1 (ko) 2023-03-21
JP7453284B2 (ja) 2024-03-19
PL3268744T3 (pl) 2021-12-27
CN107667292A (zh) 2018-02-06
MX384046B (es) 2025-03-14
US20180052164A1 (en) 2018-02-22
JP2022153482A (ja) 2022-10-12
AU2016231086A8 (en) 2022-02-03
JP2020201278A (ja) 2020-12-17
EP3268744A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
Eliasi et al. Wiener index of some graph operations
CA3280864A1 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
EP3080585A4 (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
EP3107865A4 (en) Fluorescence-based analysis of biopolymers using nanopores
EP3149465A4 (en) Electrochemical sensor for analyte detection
EP3311140B8 (en) Determining extracellular analyte concentration with nanoplasmonic sensors
EP3157429A4 (en) Extended analytical performance of continuous glucose monitoring devices via nitric oxide
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
EP3268732A4 (en) Nanopore detection of small molecules through competition assays
MX382410B (es) Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
GB201508419D0 (en) Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
IL265712B (en) A method for identifying active forms of an analyte and determining the ability of substances to bind with active sites of an analyte
EP3280821C0 (en) DETECTION OF ONE OR MORE PATHOGENS
HK1220253A1 (zh) 诊断前列腺癌症的方法
EP3292218A4 (en) COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, FORECASTING, DETECTION AND TREATMENT OF CANCER
IL249579B (en) Methods for treating, diagnosing and prognosing a haematological malignancy
WO2015035403A3 (en) Methods of assessing tumor growth by determining volumetric tumor growth
EP3176269A4 (en) Novel biomarker for predicting sensitivity to met inhibitor, and use thereof
GB201507530D0 (en) Computer-implemented methods of website analysis
EP3080596A4 (en) Highly selective coated-electrode nanogap transducers for the detection of redox molocules
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3146336A4 (en) Systems, methods, and biomarkers for determining the metabolic state of red blood cells and platelets
EP3161165A4 (en) Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
EP3112867A4 (en) Qualitative predictive method for differential diagnosis of pneumococcic, meningococcic and viral menigitis, differential meningitis diagnostic method and kit